This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).
Patients with severe brain injury are at risk for developing blood clots in their legs, which can travel to the lungs. This potentially serious complication is known as venous thromboembolism (VTE). Anticoagulants are commonly used to prevent VTE in hospital patients. However, in patients with major head injury, anticoagulant prevention is commonly delayed for the fear that it can potentially lead to further bleeding in the brain. Another method that aims to prevent blood clots involves the use of sequential compression device (SCD) that compress the legs and increase the flow of blood in the leg veins. This study will compare results from patients who receive the SCDs only to those who receive both SCD and anticoagulants. The outcome of this study will provide information about how best to prevent blood clots while not increase brain bleeding after head injury.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
1,100
Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
Saline in prophylactic doses administered daily if screening criteria are satisfied.
Foothills Medical Centre
Calgary, Alberta, Canada
RECRUITINGRoyal Alexandra Hospital
Edmonton, Alberta, Canada
RECRUITINGClinically important VTE
Composite outcome of clinically-important VTE within 7±1 days after randomization defined as any of: 1. Symptomatic, objectively-confirmed pulmonary embolism (PE), or 2. Symptomatic, objectively-confirmed, proximal leg deep vein thrombosis (DVT), or 3. Proximal (above knee) leg DVT on compression ultrasonography on Day 7±1
Time frame: 8 days
Clinically-important ICB (Intracranial bleeding) progression
Clinically-important ICB progression within 7±1 days after randomization , as defined by having (1) any increase in volume of blood in the brain on any CT scan within 7±1 days relative to initial CT scan on Day 0\* AND (2) clinical worsening within 24 hours of this CT scan, defined by one or more of the following: * Surgical intervention related to increased ICB after Day 0 (craniotomy/craniectomy, ICP monitor, external ventricular drain) * Decrease of GCS (Glasgow Coma Scale) by at least 2 points not related to sedation * Increase in ICP \>5 mmHg on 2 occasions at least 6 hours apart despite medical therapy (if ICP monitor is in place) * Death
Time frame: 7 days
Objectively confirmed new or progressing ICB on radiology,
Assessed by comparing the initial brain CT (Day 0) to that performed within 8±1 days following randomization (or most recent prior to death).
Time frame: 8 days
180-day Mortality
Mortality at 180 days
Time frame: 180 days
7-day Mortality
Mortality at 7 days
Time frame: 7 days
30-day Mortality
Mortality at 30 days
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alberta Hospital
Edmonton, Alberta, Canada
RECRUITINGVancouver General Hospital
Vancouver, British Columbia, Canada
RECRUITINGQueen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
RECRUITINGHamilton Health Sciences Centre
Hamilton, Ontario, Canada
RECRUITINGKingston General Hospital
Kingston, Ontario, Canada
RECRUITINGThe Ottawa Hospital
Ottawa, Ontario, Canada
RECRUITINGSunnybrook Health Science Centre
Toronto, Ontario, Canada
RECRUITINGUnity Health Toronto
Toronto, Ontario, Canada
RECRUITING...and 2 more locations
Delayed VTE after day 7
Any clinically important VTE occurring between Day 8 to Day 30 detected by treating clinicians
Time frame: 30 days
Functional neurological outcome at day 30 as measured by Glasgow Outcome Scale Extended
Glasgow Outcome Scale Extended (GOSE) at Day 30±5 by phone interview.
Time frame: 30 days
Functional neurological outcome at day 180 as measured by Glasgow Outcome Scale Extended
Glasgow Outcome Scale Extended (GOSE) at Day 180±14 by phone interview.
Time frame: 180 days
Quality of life outcome at 30 days as measured by the EuroQol5D
EQ-5D (EuroQol 5D) at Day 30±5 by phone interview.
Time frame: 30 days
Quality of life outcome at 180 days as measured by the EuroQol5D
EQ-5D (EuroQol 5D) at Day 180±14 by phone interview.
Time frame: 180 days